CD8A and neoplasm: To assess the effect of anlotinib administration at different stages on CD8+ T cell infiltration in tumor tissues, we performed immunohistochemical staining, which showed increased CD8+ T cell infiltration in the early-stage dosing group (An5–9) compared to the control group (Figures 6A, B).